11/1/2007 - GLP / GMP testing services in Shanghai China   Frontage Laboratories, Inc. is pleased to announce its Shanghai, P.R. China facility is in full operation, conducting GMP and GLP testing according to US and ICH guidelines. Frontage performs GLP/GMP drug development services, including bioanalytical, analytical and formulation development and testing activities for its global pharmaceutical clients at significantly reduced cost. For more information, contact us at sales@frontagelab.com.     9/5/2007 - Frontage acquires new location in Exton   Frontage announces the acquisition of an additional 25,000 sq.ft. operations space in Exton, PA. The new facility will allow Frontage to provide GMP manufacturing capabilities for oral solid dose, liquid and sterile products. Frontage will relocate the GMP Pharmaceutical Analysis and Formulation Development groups to the new facility. The new facility will also allow Frontage to create 30-40 new employment opportunities for the state of Pennsylvania.     This strategic expansion will also allow the continued expansion of the Bioanalytical services unit in Frontage's existing operations facility in Malvern, PA. Frontage has recently made significant investments in bioanalytical study reporting automation with the acquisition and implementation of Watson LIMS (by ThermoFisher), as well as in the management team and laboratory personnel. For more information about Frontage's capabilities, please contact Ron Connolly at 610-232-0100. 6/15/2007 - Frontage Laboratories acquires stake in ABR   Frontage Laboratories Acquires Equity Interest in Advanced Biomedical Research, Inc. (ABR) offering Greatly Expanded Services to Our Valued Clients     MALVERN, PA June 15, 2007/PRNewswire/ -- Frontage Laboratories (http://www.frontagelab.com), a leading high quality provider of bioanalytical, pre-clinical and drug development services to the pharmaceutical industry, announced today it has acquired a significant equity interest in Advanced Biomedical Research, Inc. (ABR) (http://www.abr-pharma.com), an international, full service CRO. With the completion of this initial phase acquisition, the combined resources of Frontage and ABR offer unparalleled formulation development, bioanalytical and GMP testing services, Phase I-II study performance in a state-of-the-art 72-bed clinical research facility, and “turn key” multinational Phase II-IV CRO services.     The combined resources of Frontage and ABR offer the following benefits to its clients:     • Single source for clinical, bioanalytical and drug development services;   • Integrated program management from discovery to commercialization;   • Proven management team;   • Proactive client-centric focus.     “Years of partnering with Frontage have already proven the synergies of our combined resources and capabilities,” commented Dr. Michael S. Willett, President and Chief Executive Officer of ABR. “Taking advantage of the opportunity to formally add Frontage’s high caliber bioanalytical services and client focused management commitment to ABR’s current offerings of clinical trial conduct and CRO services makes good sense for our respective teams as well as our clients. It will enable us to more fully meet the complete spectrum of our clients’ needs.”     Added Dr. Song Li, President and Chief Scientific Officer of Frontage, “This acquisition is a critical step in our commitment to advance our leadership position in pharmaceutical research and development by partnering with focused, like-minded professionals to provide clients with the most dedicated, caring and results-oriented services available. A key goal of our business model has been to improve the efficiency of contract drug development. The Frontage-ABR team will help our clients conserve resources and accomplish this goal in a cost effective manner.”       About Frontage Laboratories, Inc.     Frontage Laboratories, Inc. is a rapidly expanding pharmaceutical R&D services company located in the greater Philadelphia, PA area and Shanghai, P.R. China. Frontage recognizes the importance of developing cost-effective and efficacious pharmaceutical treatments; as a result, we are focused on collaborating with our clients to discover and develop new cures and healthcare advances. We are called on by leading pharmaceutical companies to solve complex development issues and advance their pharmaceutical products through FDA approval. Each employee plays an important part in the success of the organization.     Frontage Laboratories collaborates with our clients in the following areas:     • Bioanalytical services – Bioanalytical method development, validation and sample analysis supporting preclinical pharmacokinetic, toxicokinetic, and clinical pharmacokinetic studies;   • Pharmaceutical analysis – method development, validation and GMP sample testing for drug substances and finished products;   • Formulation development – immediate and sustained release tablets and capsules, injectables and oral liquids (including suspensions and emulsions), creams and ointments – product development, clinical supplies and commercialization services;   • Custom organic synthesis and API development, GMP manufacture and commercialization;   • Technology transfer of formulation and synthesis processes;   • Preclinical and biomarker research;   • Regulatory affairs and strategies;   • Data management and regulatory applications;   • Drug development and program management;   • GMP / GLP consulting services.     About Advanced Biomedical Research, Inc.   ABR is a full-service, Phase I-IV global CRO dedicated to meeting the needs of pharmaceutical, biotechnology, and medical device companies. ABR offers an extensive range of clinical services including clinical study design, strategic and regulatory consulting, project management, monitoring, clinical data management, biostatistics, pharmacokinetic and pharmacodynamic analysis, quality assurance auditing, medical writing, pharmacovigilance and regulatory submissions.   ABR’s clinical research professionals have a successful track record of executing and managing Phase II-IV multicenter trials in North America, Europe and Asia, and our accomplished team has been involved in more than 400 clinical trials since 1994. ABR’s dedicated staff employ the latest information technology to perform, manage and monitor clinical trials in a cost-efficient and rapid manner, including using internal ABR Study Tracker™, e-Vigilance™, eCTD and EDC applications and external vendor applications, such as Oracle Clinical™ (Oracle Corporation), LabPas CT™ (Green Mountain Logic), WinNonlin® (Pharsight Corporation) and SAS® (SAS Institute).   ABR has tested numerous innovator and generic compounds in its state-of-the-art Phase I-II clinical research facilities in New Jersey and performs a wide range of clinical trials including first-in-human, dose escalation, proof of concept, bioavailability, bioequivalence, PK/PD, fed-fasted, drug-drug and drug-alcohol interactions and thorough or definitive QTc evaluations.   Further information about ABR is available at www.abr-pharma.com.   ###     1/10/2007 - Frontage honored in the 2006 Philadelphia 100   Frontage Laboratories Inc. announced today that the company has been ranked 23rd in the 2006 Philadelphia 100. Hosted by the Wharton SBDC / University of Pennsylvania, the Entrepreneurs’ Forum of Greater Philadelphia and the Philadelphia Business Journal, the Philadelphia 100 honors the fastest growing, privately held companies in the Greater Philadelphia/NJ Region based upon their 3-year growth rate. Unlike other awards, the Philadelphia 100 is a merit based program.     “We are excited to be honored as one of the 2006 Philadelphia 100, ranked 23rd place among the fastest growing companies from all industries, and among the top growing pharma companies in the region,” says Song Li, PhD, President of Frontage Laboratories Inc. “Over the past 3 years, we have expanded 4 times to meet the needs of our clients and collaborators. We are at the forefront of pharmaceutical development services in China, the fastest growing global marketplace, as we established one of the first GLP/GMP facilities in that country within Shanghai’s ‘Pharma Valley,’ the Pudong Zhangjiang Hi-Tech Park. With highly skilled personnel, state-of-the-art facilities in Malvern, Pennsylvania and Shanghai, and our caring, collaborative approach to business, we are confident that we will continuously provide reliable, quality services to our clients around the world.”